Dr. Shah on Results of ZUMA-3 Study for ALL

Video

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.

Bijal Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Currently, 5-year survival rates for patients with ALL are in the range of 5% to 10%, according to Shah. There is an unmet need for additional novel therapies, which led to the introduction of KTE-X19. The therapy is unique because physicians will sort the leukemia cells out, pulling only the T-cells into the manufacturing.

Thus far, the ZUMA-3 trial has treated 45 patients with relapsed/refractory ALL with KTE-X19. Thirty patients (66%) had ≥3 prior therapies. Of the overall 45 patients, 6, 23, and 16 patients received 2, 1, and 0.5 × 106 cells/kg, respectively. All 41 patients who had ≥2 months of follow-up, the overall response rate was 68%. Of 19 pts with ≥2 of follow-up who were treated with 1 × 106 cells/kg, the complete response (CR) or CR with incomplete hematology recovery rate was 84% and the median event-free survival was 15 months.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.